CDKN2A and insomnia measurement: The current randomized clinical trial of Cognitive Behavioral Therapy for Insomnia (CBT-I) compared to a sleep education control group was effective at altering the gene expression for the biological aging biomarker p16INK4a in older adult patients initially diagnosed with insomnia.